Dasolampanel, formerly known as NGX-426, is an orally bioavailable analogue of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development for the treatment of chronic pain conditions including neuropathic pain and migraine. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed. References: Wallace MS, Lam V, Schettler J. NGX426, an oral AMPA-kainate antagonist, is effective in human capsaicin-induced pain and hyperalgesia. Pain Med. 2012 Dec;13(12):1601-10. doi: 10.1111/j.1526-4637.2012.01509.x. Epub 2012 Oct 30. PubMed PMID: 23110368.

纯度：≥98%

CAS：503294-13-1